6.82 +0.02 (0.29%)
After hours: 6:57PM EST
|Bid||6.75 x 900|
|Ask||6.84 x 800|
|Day's range||6.03 - 7.13|
|52-week range||2.20 - 27.05|
|Beta (5Y monthly)||1.72|
|PE ratio (TTM)||N/A|
|Earnings date||08 Feb 2021 - 12 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.25|
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Is (EQ) Outperforming Other Medical Stocks This Year?
If you want to know who really controls Equillium, Inc. (NASDAQ:EQ), then you'll have to look at the makeup of its...